Table 2.
Heart failure trials: number and percent of women enrolled in each and LVEF for entry
| Study | % Women | No. of Women | LVEF |
|---|---|---|---|
| A‐HeFT | 40 | 420 | ≤35% |
| CHARM–Overall | 32 | 2400 | Any |
| CHARM–Preserved | 40 | 1212 | >40% |
| CIBIS II | 19 | 515 | ≤35% |
| COMPANION | 32 | 493 | ≤35% |
| CONSENSUS | 30 | 75 | Unknown |
| COPERNICUS | 20 | 469 | <25% |
| DIG | 22 | 1520 | ≤45% |
| ELITE‐I | 33 | 240 | ≤40% |
| ELITE‐II | 31 | 966 | ≤40% |
| MADIT II | 16 | 192 | ≤30% |
| MERIT‐HF | 23 | 898 | ≤40% |
| MIRACLE | 32 | 145 | ≤35% |
| PARADIGM | 22 | 1832 | ≤40% |
| RALES | 27 | 446 | ≤35% |
| SCD HeFT | 23 | 588 | ≤35% |
| SOLVD‐Prevention | 11 | 484 | ≤35% |
| SOLVD‐Treatment | 20 | 505 | ≤35% |
| Val‐HEFT | 20 | 1003 | <40% |
| V‐HeFT I II III | 0 | 0 | <45% |
| WARCEF | 20 | 339 | <40% |
| HF ACTION | 29 | 653 | ≤35% |
Abbreviations: A‐HeFT, African‐American Heart Failure Trial; CHARM, Effects of Candesartan for the Management of Patients With Chronic Heart Failure; CIBIS, Cardiac Insufficiency Bisoprolol Study; COMPANION, Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure; CONSENSUS, Effects of Enalapril on Mortality in Severe Congestive Heart Failure; COPERNICUS, Effect of Carvedilol on Survival in Severe Chronic Heart Failure; DIG, Digoxin Investigation Group; ELITE, Evaluation of Losartan in the Elderly; HF‐ACTION, Heart Failure—A Randomized Controlled Trial Investigating Outcomes of Exercise Training; LVEF, left ventricular ejection fraction; MADIT, Multicenter Automatic Defibrillator Implantation Trial; MERIT‐HF, Metoprolol Cr/Xl Randomized Intervention Trial in Congestive Heart Failure; MIRACLE, Multicenter Insync Implantable Cardioversion Defibrillation Randomized Clinical Evaluation; PARADIGM‐HF, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure; RALES, Randomized Aldactone Evaluation Study; SCD HeFT, Sudden Cardiac Death in Heart Failure Trial; SOVLD, Effects of Enalapril on Survival in Patients With Reduced Left Ventricular Ejection; Val‐HEFT, Valsartan Heart Failure Trial; V‐HeFT, Effects of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure; WARCEF, Warfarin and Aspirin in Patients With Heart Failure and Sinus Rhythm.